MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism dementia complex(PDC)"

  • 2022 International Congress

    Plasma Alzheimer’s disease biomarkers and cognitive progression in Parkinson’s disease

    A. Pilotto, NJ. Ashton, A. Lupini, B. Battaglio, S. Gipponi, E. Cottini, I. Grossi, A. Salvi, G. de Petro, M. Pizzi, K. Blennov, M. Gonzalez, D. Aarsland, H. Zetterberg, A. Padovani (Brescia, Italy)

    Objective: To evaluate the relationship between plasma Alzheimer's disease biomarkers and cognitive progression in Parkinson's disease Background: Plasma phosphorylated tau (ptau) isoforms have been recently…
  • 2022 International Congress

    Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment

    A. Naskar, S. M, S. Sengupta, P. Pal, P. Alladi (Bengaluru, India)

    Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…
  • 2022 International Congress

    Predicting the development of dementia in patients with Parkinson’s disease by comparing neurosteroids in the blood level

    DI. Okhunova, G. Sattarovna, A. Babokhujaev (Tashkent, Uzbekistan)

    Objective: To increase the reliability of the development of dementia in patients with PD by a comparative assessment of clinical scales and neurosteroids Background: Parkinson's…
  • MDS Virtual Congress 2021

    Early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia: A Population-based Study (2010-2015).

    E. Camerucci, C. Stang, M. Hajeb, P. Turcano, A. Mullan, D. Jones, J. Graff-Radford, O. Ross, J. Bower, B. Boeve, R. Savica (Rochester, USA)

    Objective: To examine the incidence, clinical features, and survival of early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia (DLB/PDD) (≤55 years of age) in…
  • MDS Virtual Congress 2021

    A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.

    SH. Pasternak, C. Silviera, K. Coleman, E. Finger, J. Wells, M. Borrie, S. Morrow, G. Zou, R. Bartha, P. Macdonald, ME. Jenkins, M. Jog, R. Tirona, CA. Rupar (London, Canada)

    Objective: Currently there are no disease-treatments for Synucleinopathies including Parkinson’s disease dementia (PDD). Our objective is to use Ambroxol to target GBA/Glucocerebrosidase to treat PDD.…
  • MDS Virtual Congress 2021

    Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges

    SA. Atunwa (Ilorin, Nigeria)

    Objective: To evaluate anti-dementia properties of the selected herbal anti-inflammatory remedies Background: Parkinson’s disease (PD) is the most common age-related neurodegenerative disease after Alzheimer’s disease.…
  • MDS Virtual Congress 2020

    Quantitative method for designing appropriate longitudinal follow-up frequency with application to Parkinson’s disease cognition research

    L. Suttner, S. Xie (Philadelphia, PA, USA)

    Objective: To develop a quantitative method for designing appropriate longitudinal follow-up frequency. We demonstrate how to use this new method using a progression study of…
  • MDS Virtual Congress 2020

    Prevalence of Neuropsychiatric Symptoms in the Prodromal Stages of Dementia with Lewy Bodies and Parkinson’s Disease Dementia

    K. Wyman-Chick, L. Erickson, D. Weintraub, M. Rosenbloom, T. Barclay, M. Barrett (St Paul, MN, USA)

    Objective: Investigate neuropsychiatric features of prodromal stage dementia among individuals diagnosed with Lewy body disease. Background: There has been minimal investigation into the prodromal features…
  • MDS Virtual Congress 2020

    White Matter Changes and Early Cognitive Impairment in Parkinson’s Disease

    T. Belal, S. Elgamal (Mansoura, Egypt)

    Objective: Studying white matter changes in Parkinson's disease patients using diffusion tensor imaging; and its relation to cognition and motor symptoms impairment. Background: Cognitive dysfunction…
  • MDS Virtual Congress 2020

    Anxiety disorders are associated with verbal memory impairment in Parkinson’s disease

    N. Dissanayaka, E. Forbes, J. Yang, J. O'Sullivan, D. Copland, K. McMahon, L. Mitchell, G. Byrne (Brisbane, Australia)

    Objective: The present study aimed to investigate the association between anxiety disorders and memory impairment in Parkinson’s disease.The present study aimed to investigate the association…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Kratom withdrawal induced orobuccal dyskinesia
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley